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accBACKGROUND Previous studies report that CHADS2 and CHA2DS2-VASc risk scores have similar discriminating ability
(C statisticw0.6). Recently a clinically based risk score, the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation)
study risk score, was developed and validated.
OBJECTIVES This study compared predictive ability of CHA2DS2-VASc and CHADS2 ischemic stroke risk scores with
ATRIA stroke risk score and their implications for anticoagulant treatment in patients with atrial ﬁbrillation (AF).
METHODS Patients with AF not using warfarin were included from the Clinical Practice Research Datalink database,
1998 to 2012. Patients were followed from AF diagnosis until occurrence of ischemic stroke, prescription of warfarin,
death, or the study’s end. Independent predictors of ischemic stroke were identiﬁed and the c-index and net reclassiﬁ-
cation improvement were calculated.
RESULTS A total of 60,594 patients with AF were included. Annualized stroke rate was 2.99%. Event rates for moderate-
and high-risk categories for CHA2DS2-VASc were lower than those of the ATRIA and CHADS2. Age and previous stroke most
strongly predicted ischemic stroke. C statistics for the full point scores were 0.70 (95% conﬁdence interval [CI]: 0.69 to
0.71) for the ATRIA risk score, 0.68 (95% CI: 0.67 to 0.69) for CHADS2, and 0.68 (95% CI: 0.67 to 0.69) for CHA2DS2-VASc
risk score. The net reclassiﬁcation improvement was 0.23 (95% CI: 0.22 to 0.25) for ATRIA compared with CHA2DS2-VASc.
CONCLUSIONS The ATRIA score performed better in the U.K. Clinical Practice Research Datalink AF cohort. It more
accurately identiﬁed low-risk patients than the CHA2DS2-VASc score, which assigned these patients to higher-risk cate-
gories. Such reclassiﬁcation of stroke risk could prevent overuse of anticoagulants in very low stroke risk patients with AF.
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CPRD = Clinical Practice
Research Database
GP = general practitioner
HES = Hospital Episode
Statistics
NRI = net reclassiﬁcation index
TIA = transient ischemic attack
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1852A trial ﬁbrillation (AF) is one of themost common cardiac rhythm dis-orders and is associated with a
substantial risk of ischemic stroke and
thromboembolism. Various risk factors have
been associated with the occurrence of
stroke in patients with AF and several risk
scores have been developed to predict the
risk of ischemic stroke and guide the deci-
sion to treat them with anticoagulants. The
CHADS2 risk score is the simplest score and
assigns points to the presence of congestive
heart failure, hypertension, age $75, dia-
betes, and stroke (1). To better identify pa-
tients that are truly at low risk, the
CHA2DS2-VASc risk score was developed
that also included vascular disease, age be-
tween 65 and 74 years, and sex (2). Boththe U.S. and European guidelines now recommend
use of the CHA2DS2-VASc score for risk stratiﬁcation.SEE PAGE 1860The recent European Society of Cardiology guide-
line recommends treating patients with vitamin K
antagonists or novel oral anticoagulants, depending
on bleeding risk and patient preferences, when they
have moderate (score ¼ 1) or high ($2) risk according
to the CHA2DS2-VASc risk score (3). The U.S. guide-
lines, however, set the limit at 2 points or higher (4).
Previous studies have reported that the CHADS2 and
the CHA2DS2-VASc risk scores have similar discrimi-
nating ability (C statistic w0.6) (5–11). Recently a new
clinically based risk score, the ATRIA (Anti-
coagulation and Risk Factors in Atrial Fibrillation)
study risk score, was developed and validated (12).
This risk score uses factors incorporated in the
CHADS2 risk score, but added renal dysfunction. A
broader range and increased weighting of age cate-
gories was used and the interaction of age and prior
stroke was incorporated in the model, reﬂecting a
high risk of stroke for patients with AF with a history
of stroke regardless of age.
This study compares the predictive ability of the
ATRIA risk score with the CHADS2 and CHA2DS2-VASc
risk scores in a large, independent, community-based
cohort of patients with AF.d research funding from public sources (e.g., Netherlands Organ
lth Care Insurance Board, EU 7th Framework Program, Dutch M
. Staa has participated in an expert meeting on simple trials for Bo
s no relationships relevant to the contents of this paper to disclo
received June 5, 2015; revised manuscript received July 28, 2015METHODS
STUDY POPULATION. Information for this study was
obtained from the Clinical Practice Research Datalink
(CPRD), which contains the computerized medical
records of more than 10 million patients registered
with general practitioners (GPs) in the United
Kingdom. The data include demographic information,
prescription details, clinical events, preventive care
provided, specialist referrals, hospital admissions,
and major outcomes. About 50% of the practices in
CPRD have been linked to other datasets in England,
such as the Hospital Episode Statistics (HES). The HES
includes records of inpatient hospitalizations, such
as date of admission and discharge, diagnoses, and
procedures performed. The current study used only
practices that have been linked to HES.
The study population consisted of patients aged 18
years or older with a ﬁrst AF diagnosis during the
period of data collection (from January 1998 through
January 2012). Patients with a record of rheumatic
mitral stenosis and those with a prosthetic heart
valve were excluded because of their altered stroke
risk, resulting in a typical “nonvalvular” AF popula-
tion. The index date was the date of ﬁrst AF diag-
nosis. Patients were followed from the index date
until the primary outcome occurred, end of data
collection, or the date of the ﬁrst warfarin prescrip-
tion, whichever date came earliest. The primary
outcome was ischemic stroke recorded either in CPRD
(according to Read coding), HES (according to Inter-
national Classiﬁcation of Disease-10 codes), or both to
ensure completeness of information.
UNIVARIABLE AND MULTIVARIABLE ANALYSIS OF
RISK FACTORS. Multiple potential risk factors for
ischemic stroke were identiﬁed: age, body mass index,
smoking status, number of visits to the GP, ethnicity,
socioeconomic status, history of congestive heart
failure, hypertension, diabetes mellitus, vascular dis-
ease (i.e., angina pectoris, myocardial infarction),
prior stroke or transient ischemic attack (TIA), deep
venous thrombosis or pulmonary embolism, major
bleeding event, proteinuria, and renal dysfunction.
Diagnostic codes were extracted from both HES (In-
ternational Classiﬁcation of Disease-10 codes) (Online
Table 1) and CPRD (Read codes) (Online Appendix 1).isation for Health Research and Development, the
edicines Evaluation Board, and Dutch Ministry of
ehringer Ingelheim. Mrs. van den Ham has reported
se.
, accepted August 4, 2015.
TABLE 2 Overview of Used Risk Scores: Risk Factors Used in
CHA2DS2-VASc Risk Score and CHADS2 Risk Score
Score
CHA2DS2-VASc Risk Score
Congestive heart failure/LV dysfunction 1
Hypertension 1
Age $75 yrs 2
Diabetes mellitus 1
Stroke/TIA/TE 2
Vascular disease (prior myocardial infarction,
peripheral artery disease, or aortic plaque)
1
Age 65–74 yrs 1
Sex category (female/male) 1
CHADS2
Congestive heart failure 1
Hypertension 1
Age $75 yrs 1
Diabetes mellitus 1
History of stroke/TIA 2
CHADS2 ¼ congestive heart failure, hypertension, age $75, diabetes, and stroke;
CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75, diabetes,
stroke, vascular disease, age between 65-74, and female sex; LV ¼ left ventricular;
TE ¼ thromboembolic event; TIA ¼ transient ischemic attack.
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1853For renal failure and proteinuria, laboratory test re-
cords were used in addition to diagnostic codes. Renal
dysfunction was deﬁned as an estimated glomerular
ﬁltration rate of <60 ml/min/1.73 m2 or a diagnosis of
renal failure (13). Patients that did not have a labora-
tory value or a diagnostic code for renal failure or
proteinuria were assumed to have normal values. All
risk factors were assessed at baseline. Stepwise back-
ward selection of risk factors was used with a signiﬁ-
cance level for removal from the model of 0.20. An
indicator variable for “missingness” was included in
the model. With the risk factors left in the model we
tested the presence of statistical interaction with age
and sex. The interaction term was considered strong
enough for inclusion in the ﬁnal model when found
statistically signiﬁcant after Bonferroni adjustment of
the signiﬁcance level. When interaction tests are done
for individual combinations of predictors, a stringent
p value should be used (14).
COMPARING RISK SCORES. The 1-year risk of
ischemic stroke was calculated for each patient ac-
cording to the ATRIA, CHADS2, and CHA2DS2-VASc
risk scores. The risk factors and weightings that
were considered for each risk score are listed in
Tables 1 and 2. The C statistic, a measure of the area
under the receiver operating characteristic curve, was
calculated to determine the predictive ability of each
risk score to discriminate between patients who
developed the outcome and those that did not. We
presented 95% conﬁdence interval (CI) using the
jackknife method (15). A C statistic of $0.5 indicates
that the risk score performs better than chance. The
net reclassiﬁcation index (NRI) was also calculated to
assess the proportion of person-years correctly up-
plus down-reclassiﬁed when using the ATRIA riskTABLE 1 Overview of Used Risk Scores: Risk Factors Used in
ATRIA Risk Score
Risk Factor
Points Without
Prior Stroke
Points With
Prior Stroke
Age, yrs
$85 6 9
75–84 5 7
65–74 3 7
<65 0 8
Female 1 1
Diabetes mellitus 1 1
CHF 1 1
Hypertension 1 1
Proteinuria 1 1
eGFR <45 or ESRD 1 1
ATRIA ¼ Anticoagulation and Risk Factors in Atrial Fibrillation; CHF ¼ congestive
heart failure; eGFR ¼ estimated glomerular ﬁltration rate; ESRD ¼ end-stage renal
disease.score instead of the conventional CHA2DS2-VASc
and CHADS2 risk scores (15,16). Threshold rates of
ischemic stroke of 1% and 2% per year were used to
discriminate between low-, moderate-, and high-risk
categories. These limits were chosen on the basis of
a published decision model that investigated the
tipping point at which the beneﬁts and risks of
taking anticoagulants were balanced (17). All statis-
tical analyses were performed using SAS software,
version 9.2 (SAS Institute, Cary, North Carolina).
SENSITIVITY ANALYSIS. Several sensitivity analyses
were carried out to test the robustness of our ﬁnd-
ings. In both CPRD and HES, stroke events are in some
cases not speciﬁed as ischemic or hemorrhagic and
registered as “stroke unspeciﬁed.” These events were
assumed in our analysis to be ischemic strokes. In a
sensitivity analysis we excluded these unspeciﬁed
events to assess the impact on our ﬁndings. In 29% of
patients there was missing information on renal
function. We assessed if the performance of the
ATRIA score would change without including infor-
mation on renal dysfunction. Friberg et al. (18)
recently recommended excluding events that occur
immediately following the initial diagnosis of AF (the
“blanking period”) to prevent an overestimation of
the stroke risk associated with AF. Therefore, we
performed a sensitivity analysis in which a 4-week
blanking period was included to compensate for an
initial high stroke rate. We observed lower stroke
rates in the second half of follow-up: 3.5% per year
versus 2.8% per year. As a sensitivity analysis, we
TABLE 3 Baseline Characteristics of the Study Population
Risk Factor Level
Patients With AF
(n ¼ 60,594) %
Follow-up, yrs Mean 2.81
Median 0.74
Percentiles 5th-95th 0.02–8.13
Interquartile range 0.13–3.13
Age, yrs Mean 74.4
Age category, yrs <65 11,742 19.4
65–74 14,923 24.6
75–84 21,637 35.7
$85 12,292 20.3
Sex Male 31,088 51.3
BMI, kg/m2 Underweight 2,736 4.5
Normal weight 15,722 25.9
Overweight 19,746 32.6
Obese 13,491 22.3
Not recorded 8,899 14.7
GP visits $20 40,381 66.6
Smoking Nonsmoking 30,298 50.0
Current-smoking 9,421 15.6
Ex-smoking 17,272 28.5
Not recorded 3,603 6.0
Diabetes mellitus 7,397 12.2
Congestive heart failure 10,571 17.5
Hypertension 33,026 54.6
Stroke/TIA 8,916 14.7
Vascular disease 18,636 30.8
Proteinuria 1,756 2.9
Renal dysfunction
(eGFR <60 ml/min/1.73 m2)
16,990 28.0
AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; GP ¼ general practitioner; other abbreviations as in
Tables 1 and 2.
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1854repeated our comparison of the 3 stroke risk schemes
limiting the study population to those in years 2005
to 2012. Finally, the risk scores were also tested when
the point score cutoffs were optimized to ﬁt the 1%
and 2% thresholds in the current dataset for the
CHADS2 (0, 1, 2 to 6 points), CHA2DS2-VASc (0 to 1, 2, 3
to 9), and ATRIA (0 to 2, 3 to 5, 6 to 15) risk scores.
RESULTS
The study population included 60,594 patients with
AF untreated with warfarin. Approximately 3,000
patients per year were included in 1998 to 2000, and
4,000 to 5,000 patients per year were included from
2001 onward. The mean follow-up time (from the date
of the AF diagnosis up to start of warfarin or end of
data collection) was 2.1 years and the mean age at
entry to the cohort was 74.4. Table 3 shows commonly
recorded diagnoses, including hypertension (54.6%),
vascular diseases (30.8%), and renal dysfunction
(28.0%). A total of 3,751 ischemic strokes occurred
during the follow-up period of 125,296 person-years,
yielding an annualized rate of 2.99%.The hazard ratios (HRs) of the clinical risk pre-
dictors from the univariable and multivariable anal-
yses are shown in Table 4. Increasing age was a
particularly strong risk factor among patients without
a history of prior stroke or TIA. For example, among
those patients, age 65 to 74 years conferred a HR of
2.87 (95% CI: 2.40 to 3.42) compared with younger
patients. The effect of age was muted among patients
who had had a prior stroke or TIA. Even relatively
young patients with a history of prior stroke or TIA
were at high risk for a subsequent stroke. The inter-
action between age and prior stroke was statistically
signiﬁcant (p < 0.001). Several other signiﬁcant risk
factors were conﬁrmed. Small multivariable associa-
tions were found including female sex (HR: 1.23; 95%
CI: 1.14 to 1.32), hypertension (HR: 1.14; 95% CI: 1.06
to 1.22), and diabetes mellitus (HR: 1.24; 95% CI: 1.12
to 1.37). Vascular disease, major bleed, renal
dysfunction (estimated glomerular ﬁltration rate
<60 ml/min/1.73 m2), and congestive heart failure
were associated with a higher risk in the univariate
but not multivariate analysis.
The Central Illustration shows the proportion of
patients that were classiﬁed at low, moderate, or high
risk for ischemic stroke according to each of the
different risk scores. The ATRIA risk score classiﬁed
49.0% of patients into the high-risk category and
40.0% as low, whereas the CHA2DS2-VASc risk score
classiﬁed 82.6% as high and 6.6% as low risk.
The C statistics for the continuous risk scores were
0.70 (95% CI: 0.69 to 0.71) for the ATRIA risk score,
0.68 (95% CI: 0.67 to 0.69) for the CHADS2, and 0.68
(95% CI: 0.67 to 0.69) for the CHA2DS2-VASc risk
score. The categorical risk scores, using the published
low/moderate/high risk cutoffs (Table 5) resulted in
C statistics of 0.66 (95% CI: 0.66 to 0.67) for the
ATRIA, 0.65 (95% CI: 0.64 to 0.66) for the CHADS2,
and 0.59 (95% CI: 0.59 to 0.60) for the CHA2DS2-VASc
risk score.
Table 5 shows ischemic stroke event rates stratiﬁed
by the different risk scores. The event rates for the
moderate- and high-risk categories for CHA2DS2-VASc
were lower than those of the ATRIA and CHADS2 risk
scores. The event rate in the moderate-risk category
of the CHA2DS2-VASc risk score (1 point) was 0.78 per
100 person-years. When we excluded individuals
whose only risk factor was being female, the annual
rate of stroke was 0.36%.
The NRI was 0.137 (95% CI: 0.120 to 0.153) or 0.233
(95% CI: 0.219 to 0.248) when using the ATRIA versus
the CHADS2 or CHA2DS2-VASc risk scores, respec-
tively. These improvements resulted mainly from
downward reclassiﬁcation from the CHADS2 score and
entirely from downward reclassiﬁcation from the
TABLE 4 Risk Factors for Ischemic Stroke in Patients With AF
Risk Factor Level
Ischemic Stroke
Rate Per 100
Person-Years
HR (95% CI)
Crude
HR (95% CI)
Adjusted*
Age  prior stroke/TIA, yrs <65, stroke 6.63 10.63 (8.0–14.15) 10.58 (7.93–14.12)
65–74, stroke 8.01 12.67 (10.63–15.53) 12.37 (10.04–15.23)
75–84, stroke 8.77 13.99 (11.74–16.66) 13.10 (10.91–15.73)
$85, stroke 10.56 16.46 (13.73–19.73) 14.94 (12.33–18.09)
<65, no stroke 0.57 Reference Reference
65–74, no stroke 1.75 2.96 (2.48–3.52) 2.87 (2.40–3.42)
75–84, no stroke 3.05 5.14 (4.37–6.03) 4.80 (4.07–5.66)
$85, no stroke 4.46 7.30 (6.19–8.62) 6.55 (5.50–7.78)
Sex Male 2.37 Reference Reference
Female 3.59 1.54 (1.43–1.64) 1.23 (1.14–1.32)
BMI, kg/m2 Underweight 3.82 1.22 (1.05–1.42) 1.08 (0.93–1.25)
Normal weight 2.99 Reference Reference
Overweight 2.94 0.97 (0.89–1.06) 1.02 (0.94–1.11)
Obese 2.48 0.79 (0.72–0.88) 0.92 (0.83–1.03)
Not recorded 3.47 1 .19 (1.08–1.30) 1.17 (1.05–1.29)
GP visits <20 2.43 Reference Reference
$20 3.40 1.29 (1.21–1.38) 0.92 (0.85–0.99)
Smoking Nonsmoking 0.78 Reference Reference
Current-smoking 10.67 0.84 (0.76–0.93) 1.08 (0.97–1.19)
Ex-smoking 2.94 0.90 (0.83–0.97) 0.98 (0.90–1.06)
Not recorded 2.97 1.01 (0.9–1.14) 0.94 (0.82–1.08)
Antiplatelet agents 3.60 1.43 (1.34–1.52) 0.97 (0.90–1.04)
Diabetes mellitus 4.01 1.30 (1.18–1.43) 1.24 (1.12–1.37)
Congestive heart failure 4.25 1.41 (1.30–1.53) 1.03 (0.94–1.12)
Hypertension 3.70 1.48 (1.38–1.58) 1.14 (1.06–1.22)
Vascular disease 3.54 1.23 (1.15–1.31) 0.98 (0.91–1.06)
Proteinuria 3.75 1.14 (0.93–1.39) 0.98 (0.80–1.21)
Renal dysfunction 4.30 1.53 (1.42–1.63) 1.06 (0.98–1.14)
Major bleed 3.61 1.17 (1.06–1.30) 0.95 (0.86–1.05)
DVT/PE 3.74 1.18 (0.89–1.56) 0.82 (0.62–1.09)
*Adjusted by age, sex, diabetes, hypertension, renal dysfunction, social economic status, smoking status, stroke, vascular disease, and usage of antiplatelet agents at baseline.
CI ¼ conﬁdence interval; DVT ¼ deep venous thrombosis; HR ¼ hazard ratio; PE ¼ pulmonary embolism; other abbreviations as in Tables 2 and 3.
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1855CHA2DS2-VASc score. The performance of the ATRIA
risk score did not change signiﬁcantly when renal
dysfunction was removed from the risk score. When
“unspeciﬁed” strokes were excluded, or when a
blanking period of 4 weeks was used, the overall
stroke rates decreased but the relative performance of
the ATRIA risk score persisted. In addition, we
restricted the analysis to the second half of the study
(see the Methods section) including 44,784 patients
and 2,362 events. The C statistic and NRIs did not
differ from the main analysis. The results of these
sensitivity analyses can be found in Online Table 2.
The risk scores were also tested when the point
score cutoffs were optimized to ﬁt the 1% and 2%
thresholds in the current dataset for the CHADS2 (0, 1,
2 to 6 points), CHA2DS2-VASc (0 to 1, 2, 3 to 9), and
ATRIA (0 to 2, 3 to 5, 6 to 15) risk scores. Using these
optimized cutpoints, the C statistic for the 3-category
CHADS2 and CHA2DS2-VASc risk score improved to0.65 (95% CI: 0.64 to 0.66) and 0.63 (95% CI: 0.62 to
0.64), respectively, whereas the C statistic for the
ATRIA score did not change. The NRI for ATRIA
decreased to 0.033 (95% CI: 0.021 to 0.046) compared
with the CHADS2 risk score and 0.084 (95% CI: 0.076
to 0.093) compared with the CHA2DS2-VASc risk
score.
DISCUSSION
This study found that the ATRIA risk score performed
better than the CHADS2 and CHA2DS2-VASc risk scores
with a higher C statistic and positive NRI. This pattern
persisted in sensitivity analyses where we restricted
the analysis to the more recent half of the cohort’s
follow-up period, when we excluded “unspeciﬁed”
strokes as outcome events and when we excluded
renal dysfunction as a predictor. The improvement in
risk classiﬁcation resulted mainly from downward
CENTRAL ILLUSTRATION Comparing Risk Scores for the Prediction of
Stroke in Atrial Fibrillation: ATRIA, CHADS2, and CHA2DS2-VASc
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van den Ham, H.A. et al. J Am Coll Cardiol. 2015; 66(17):1851–9.
Percentages of patients classiﬁed into low, moderate, and high risk according to the
ATRIA, CHADS2, and CHA2DS2-VASc risk scores. ATRIA ¼ Anticoagulation and Risk Factors
in Atrial Fibrillation; CHADS2 ¼ congestive heart failure, hypertension, age $75, diabetes,
and stroke; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75, diabetes,
stroke, vascular disease, age between 65-74, and female sex.
TABLE 5 Ischemic Stroke Event Rates Stratiﬁed by the Sum of Points for ATRIA, CHADS2, an
Points
ATRIA CHADS2
Events PY  1,000
Rate per
100-PY OR (95% CI) Events PY  1,000
Rate per
100-PY
0 51 12.8 0.40 Reference 250 32.1 0.78
1 70 11.6 0.60 933 40.1 2.33
2 31 4.2 0.73 1,117 31.7 3.52 2.8
3 93 7.1 1.31 661 12.4 5.34
4 194 10.3 1.89 598 6.7 8.98 5.
5 251 12.6 1.99 162 2.1 7.90
6 338 14.4 2.35 1.97 (1.73–2.24) 30 0.3 11.50
7 531 14.9 3.57 4.17 (3.84–4.54)
8 687 14.0 4.91
9 642 11.1 5.80
10 415 7.3 5.69
11 272 3.3 8.26
12 127 1.3 9.47
13 42 0.4 10.89
14 7 0.0 14.26
15 0 0.0 0.00
All 3,751 125.3 2.99
Black lines identify threshold for low-, moderate-, and high-risk categories for the 3 stroke risk point scores using th
OR ¼ odds ratio; PY ¼ person-years; other abbreviations as in Tables 1, 2, and 4.
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1856reclassiﬁcation. Patients with a CHA2DS2-VASc risk
score of 1 seem to have an absolute risk of <1%. As a
consequence, applying the CHA2DS2-VASc risk score
in a community-based population, such as the CPRD,
might lead to overtreatment of very low stroke risk
patients.
The C statistics of all risk scores showed moderate
discriminative ability. However, the C statistic has
proved to be inelastic and shows little improvement
when important risk factors are added to the predic-
tion model. Examples of this (change of 0.01 to 0.02
in C statistic) include individual well-known and
proved risk factors, such as systolic blood pressure,
smoking, and total cholesterol in predicting coronary
heart disease (19). The NRI is a measure that attempts
to quantify the added predictive ability of a new
marker by assessing the proportions of patients (or
patient-years) that are correctly reclassiﬁed into
broad risk categories when using a different model.
These categories are relevant to treatment decisions.
Our ﬁndings were consistent with the original report
of the ATRIA stroke risk score (12).
The CHA2DS2-VASC risk score was developed to
identify those patients who are truly at low risk (2).
As a consequence, fewer patients are assigned to the
low-risk category with the CHA2DS2-VASC risk score
than when using ATRIA or CHADS2 risk scores. There
is debate about the threshold at which patients
should be treated. A simulation study of Eckman et al.d CHA2DS2-VASc Risk Scores
CHA2DS2-VASc
OR (95% CI) Events PY  1,000
Rate per
100-PY OR (95% CI)
Reference 45 11.8 0.38 Reference
130 16.8 0.78 1.99 (1.42–2.80)
9 (2.51–3.32) 412 21.5 1.92 8.96 (6.68–12.02)
766 27.0 2.84
71 (5.01–6.51) 896 24.2 3.70
702 13.8 5.08
472 6.7 7.09
235 2.6 8.98
79 0.9 9.01
14 0.1 15.49
e published cutpoints.
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ment should be at a stroke rate of 1.7% per year. In
the CPRD population, the event rate in the CHA2DS2-
VASc moderate-risk category was about one-half of
that. Preferably, patients with these low stroke risks
should not be treated with vitamin K antagonists.
The most recent European Society of Cardiology
guideline does not consider female sex as a stand-
alone risk factor. Even if we exclude individuals
whose only risk factor was being female, the annual
rate of stroke for patients with a CHA2DS2-VASC risk
score of 1 was very low at 0.36%. The same paper by
Eckman et al. showed that the threshold for treat-
ment with a new oral anticoagulant is 0.9% per year,
because these agents seem to pose a lower risk of
intracranial bleeding (20). But, even this risk
threshold is higher than the stroke rate observed for
patients with a CHA2DS2-VASC risk score of 1.
Because the risk category thresholds that we used
were ﬁxed at 1% and 2% per year, the proportions of
patients accurately classiﬁed varies with the reported
stroke rates in different cohorts. The ATRIA risk score
was developed on a cohort with an overall stroke rate
of 2% per year, whereas the CPRD AF cohort rate was
3% per year. The ﬁt of the CHADS2 and CHA2DS2-VASc
risk scores was improved by adjusting the point score
thresholds for low and high risk. With such optimized
thresholds the NRI advantage of the ATRIA score
diminished but was still positive. In case of any new
evidence on different cutoff points for the discrimi-
nation between low-, moderate-, and high-risk
groups, the NRI will be affected. For example, if the
threshold is set higher (2% and 3%), ATRIA performs
better.
Recently, 2 studies reported that the CHA2DS2-
VASc score was superior to the ATRIA score in clas-
sifying low-risk patients in a Danish national cohort
and a Taiwanese national cohort of patients with AF
(21,22). The absolute stroke rates reported for these
cohorts were much higher than those that we
observed for the U.K. CPRD AF cohort, and this likely
explains much of the difference in results. For ATRIA
point scores of 0 to 5 (i.e., the original ATRIA low-risk
category) the absolute stroke risk was 1.18% per year
for the U.K. CPRD cohort that we studied, 3.22% per
year for the Danish cohort, and 2.95% for the Taiwa-
nese cohort. This highlights the variation in stroke
rate among different cohorts, but also differences in
methods used for detecting stroke cases in these
electronic health care databases. As a point of refer-
ence, previous studies of the Danish cohort (8) re-
ported stroke rates substantially higher than a similar
Swedish national AF cohort (6). For patients in
CHA2DS2-VASc score strata of 0 to 3 points the strokerates observed in the Swedish AF cohort and the U.K.
CPRD cohort are in close agreement. Friberg et al. (18)
studied the impact of variation in the deﬁnition of
stroke in the Swedish cohort and found that for pa-
tients with AF and a CHA2DS2-VASc score of 1 the
stroke rate is lower than previously reported. This
was attributed to the inclusion or exclusion of TIAs
and pulmonary embolism, including patients with a
secondary diagnosis of stroke, and considering an
initial blanking period (18,23). In the current study we
demonstrated that the blanking period did change the
absolute stroke rate, but did not affect the relative
performance of the risk scores. This may be due to the
fact that the AF diagnosis in CPRD is recorded by the
GP and not in the hospital as is done in the Swedish
database. A diagnosis in the hospital can be a sec-
ondary AF diagnosis when a patient seeks medical
attention because of an unrelated acute disease,
whereas the GP often records a true incident AF case.
The difference in stroke rate is probably mostly
explained by the difference in deﬁnition and ascer-
tainment of stroke rather than by true differences in
stroke rates, although this issue needs further study.
There have been numerous studies that identiﬁed
independent risk factors for ischemic stroke (24).
We conﬁrmed that female sex, increasing age, prior
stroke, hypertension, and diabetes are independent
risk factors of ischemic stroke. We did not ﬁnd any
independent association of stroke with vascular dis-
ease, a distinctive component of the CHA2DS2-VASc
score. We also did not ﬁnd that congestive heart fail-
ure was a risk factor for stroke, a component of all 3
scores. This questions the value of inclusion of this
risk factor in all risk scores. In the CPRD database we
used a record of a clinical diagnosis for heart failure.
This was not supported with echocardiographic evi-
dence, whichmight lead tomisclassiﬁcation and affect
the reliability of this risk factor (25). These ﬁndings are
consistent with results from the Swedish AF cohort in
which independent risk factors were studied (6).
Several studies have investigated the importance
of renal failure and proteinuria in relation with
ischemic stroke (26–28). It is likely that this is an
important risk factor for ischemic stroke, considering
that this is closely related to the pathophysiology of
heart failure, hypertension, diabetes mellitus, and
vascular disease. In the current study we did not ﬁnd
an association of renal dysfunction and proteinuria
with ischemic stroke in the multivariable analysis.
However, renal function and proteinuria are variables
that are not regularly registered in the CPRD database
and information may therefore be incomplete.
Furthermore, because laboratory values are often
reported in chronic kidney disease classes in the
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
decision to anticoagulate patients with atrial ﬁbrilla-
tion should be based on their risk of ischemic stroke.
The ATRIA, CHADS2, and CHA2DS2VASc risk scores all
perform modestly, with the ATRIA score slightly
superior to the others in identifying low-risk patients
who do not beneﬁt from anticoagulation.
TRANSLATIONAL OUTLOOK: Further studies are
needed to assess the extent to which incorporation of
additional information, such as ethnicity, biochemical
or genetic markers, and cardiovascular imaging
ﬁndings, could enhance stroke risk stratiﬁcation in
patients with atrial ﬁbrillation.
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1858database, we were not able to take the cutoff esti-
mated glomerular ﬁltration rate of <45 ml/min/1.73 m2,
as is used in the ATRIA risk score. Instead we used
the cutoff at chronic kidney disease category 3
(<60 ml/min/1.73 m2). Misclassiﬁed renal function
might have reduced the performance of the ATRIA
score to a small extent. The ATRIA score assigns a
much higher weighting to increasing age categories.
These weightings are consistent with our analysis of
the CPRD AF cohort and likely contribute to the better
performance of the ATRIA score.
STUDY LIMITATIONS. Accurate information on out-
comes and risk factors is very important in devel-
oping prediction studies. Several studies have
validated the accuracy and completeness of the data
recorded in CPRD (29,30). Herrett et al. (29) found
that for diagnoses in the disease group of the circu-
latory system, 85.3% of cases were conﬁrmed. How-
ever, patients who do not regularly visit their
physicians are less likely to have risk factors identi-
ﬁed. Undetected risk factors lead to overestimates of
stroke rates in low point score categories. Another
limitation concerns the classiﬁcation of type of
stroke. Some events of stroke are recorded as un-
speciﬁed stroke in CPRD. We assumed that
these cases of stroke were ischemic, which could have
resulted in a misclassiﬁcation. However, in a sensi-
tivity analysis, in which we only used the deﬁnite
cases of ischemic stroke, there were no major differ-
ences in results.
CONCLUSIONS
The ATRIA, CHADS2, and CHA2DS2-VASc risk scores
for the prediction of ischemic stroke in AF perform
modestly, with the ATRIA risk score performing best.
This study underlines the fact that the performance of
low-, moderate-, and high-risk point score thresholds
is sensitive to absolute population stroke rates.Wide differences in reported rates of ischemic
strokes across cohorts need to be investigated to
separate true variation in rates from variation caused
by methodologic inconsistencies. Current guide-
lines advise to use anticoagulants in patients with
CHA2DS2-VASc risk score of >0, but this cutoff
and this risk score approach might be reconsidered
because patients tend to have lower absolute risks in
community-based populations. Better risk prediction
can reduce overuse of anticoagulation in low stroke
risk patients with AF, while at the same time guiding
the appropriate use in patients at higher risk of stroke.
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